Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Director Purchases $16,000.00 in Stock

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Director Adam K. Stern acquired 20,000 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were acquired at an average price of $0.80 per share, with a total value of $16,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of MTNB traded down $0.03 during midday trading on Friday, reaching $0.80. 561,082 shares of the stock were exchanged, compared to its average volume of 1,039,420. Matinas BioPharma Holdings Inc has a 12-month low of $0.32 and a 12-month high of $1.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.01).

A number of equities research analysts have commented on MTNB shares. BTIG Research started coverage on Matinas BioPharma in a research report on Friday, May 17th. They set a “buy” rating and a $5.00 price objective for the company. Maxim Group reaffirmed a “buy” rating and set a $5.00 price target on shares of Matinas BioPharma in a research note on Thursday, May 16th. Finally, Zacks Investment Research raised Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Tuesday, April 16th.

Hedge funds have recently modified their holdings of the stock. D. E. Shaw & Co. Inc. bought a new position in shares of Matinas BioPharma in the 4th quarter valued at approximately $26,000. Private Advisor Group LLC raised its stake in shares of Matinas BioPharma by 100.4% in the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after acquiring an additional 24,978 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new position in shares of Matinas BioPharma in the 1st quarter valued at approximately $39,000. ExodusPoint Capital Management LP bought a new position in shares of Matinas BioPharma in the 1st quarter valued at approximately $42,000. Finally, Jane Street Group LLC raised its stake in shares of Matinas BioPharma by 190.1% in the 1st quarter. Jane Street Group LLC now owns 41,452 shares of the company’s stock valued at $45,000 after acquiring an additional 27,165 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/06/14/matinas-biopharma-holdings-inc-nyseamericanmtnb-director-purchases-16000-00-in-stock.html.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Read More: Trading Penny Stocks

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.